Delivery Order SPE2DB22D3501-SPE2DB25FXF04
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Revlimid 15 mg capsules (21-count packages) under a firm fixed-price contract with a ceiling value of $32,771.71. This competitively awarded, non-set-aside delivery order is scheduled for completion by September 4, 2025, with fulfillment performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award represents a continuation of the company's...
- The Defense Logistics Agency awarded a $27,425.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Revlimid 2.5 mg capsules (28-count units), with an ultimate completion date of September 29, 2025. This non-set-aside competitive award was issued on September 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $52,487.80 by the Defense Logistics Agency on August 28, 2025, for the supply of Revlimid 25 mg capsules (100-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 19, 2025, and will be performed at the awardee's Conshohocken location. The contract carries no set-aside designation,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $52,487.80 by the Defense Logistics Agency for the supply of Revlimid 25 mg capsules (100-count units). The award, issued on August 19, 2025, with an ultimate completion date of September 10, 2025, represents a firm fixed-price delivery order with no set-aside designation. This contract was competitively awarded and will be performed at the...
- The Defense Logistics Agency awarded a delivery order valued at $12,329.16 to AmerisourceBergen Drug Corp for the supply of Revlimid 5 mg capsules (28-count) under a Firm Fixed Price contract with an ultimate completion date of September 3, 2025. This non-set-aside award was competitively awarded and represents a direct fulfillment of pharmaceutical supply needs for federal medical procurement, with performance conducted at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $105,150.98 for Revlimid 10 mg capsules (100-count units) on August 20, 2025, with an ultimate completion date of September 11, 2025. This is a firm fixed price, non-set-aside contract performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award is a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $52,575.49 to AmerisourceBergen Drug Corp for 100 capsules of REVLIMID 10 mg on August 8, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply framework with DLA. The pharmaceutical product will be delivered to the company's corporate office location in...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for $49,926.80. The order is for REVLIMID 10 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of October 9, 2024 and is a firm fixed-price contract. AmerisourceBergen, a major pharmaceutical distributor, is the prime contractor. This order is likely part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Revlimid 10 mg capsules. The contract has a firm fixed price of $178,310.12 and a period of performance through August 8, 2024. The award is not set aside for any specific business type. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 with the DLA Troop Support Medical for delivering a wide range...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded a $24,963.40 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the supply of REVLIMID 5 MG CAPSULE 28S, a pharmaceutical product, and has an ultimate completion date of October 3, 2024. This order is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXF04Delivery Order
The Defense Logistics Agency awarded a $19.85K firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Revlimid 15 mg capsules (21-count packaging) on September 8, 2025, with completion required by September 29, 2025. This non-set-aside competitive award supports federal pharmaceutical procurement needs, with performance taking place at the contractor's Conshohocken, Pennsylvania headquarters. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999.99B prime vendor agreement running through December 2026 that enables the contractor to supply pharmaceutical products and medical supplies globally to military healthcare systems. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to deliver a comprehensive range of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains. This award reflects AmerisourceBergen's continued role as a primary pharmaceutical supplier within DLA's medical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.9k | 9/8/25 |